Amnio Technology News
Amnio Technology, LLC Announces the Initiation of a Phase 2 Clinical Trial to Evaluate PalinGen® Flow for the Treatment of Venous Stasis and Diabetic Ulcers
Phoenix, October 20, 2020 Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that it has received authorization from FDA to proceed with a Phase 2 clinical trial under an Investigational...
Amnio Technology Awarded MedTech Wound Care’s Top 10 Solution Providers of 2019
PHOENIX, December 16, 2019 — Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, is honored to have been awarded MedTech Wound Care's Top 10 Solution Providers of 2019. About Amnio Technology, LLC...
Amnio Technology announces national launch of PalinGen® InovōFlo™ to supplement tissue for protection, cushioning and lubrication
PHOENIX, Sept. 5, 2017 /PRNewswire/ -- Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, announced today the expansion of its product line with the launch of PalinGen® InovōFlo™. PalinGen®...
Amnio Technology receives first US Patent for placental tissue allograft
Accelular amnion derived therapeutic compositions. Amnion derived materials are being used to treat a wide array of conditions such as to promote tissue healing.
Amnio Technology News
Amnio Technology, LLC Announces the Initiation of a Phase 2 Clinical Trial to Evaluate PalinGen® Flow for the Treatment of Venous Stasis and Diabetic Ulcers
Phoenix, October 20, 2020 Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that it has received authorization from FDA to proceed with a Phase 2 clinical trial under an Investigational...
Amnio Technology Awarded MedTech Wound Care’s Top 10 Solution Providers of 2019
PHOENIX, December 16, 2019 — Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, is honored to have been awarded MedTech Wound Care's Top 10 Solution Providers of 2019. About Amnio Technology, LLC...
Amnio Technology announces national launch of PalinGen® InovōFlo™ to supplement tissue for protection, cushioning and lubrication
PHOENIX, Sept. 5, 2017 /PRNewswire/ -- Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, announced today the expansion of its product line with the launch of PalinGen® InovōFlo™. PalinGen®...
Amnio Technology receives first US Patent for placental tissue allograft
Accelular amnion derived therapeutic compositions. Amnion derived materials are being used to treat a wide array of conditions such as to promote tissue healing.